News About: Pharm. Industry
A new subsidy system may let pharmaceutical companies get damages
From September 1, ‘prescription subsidy system’ starts and pharmaceutical industries keep an eye on the influence that it would make.
This new system still includes incentive factors, so pharmaceutical industries ex...
DongaST requested permission of superbacteria-targeted antibiotics
On August 29th, DongaST submitted new drug application to the Ministry of Food and Drug Safety for releasing SIVEXTRO in domestic market. SIVEXTRO(main component: Tedizolid Phosphate) is Super Bacteria-targeted antibi...
Incresing selling causes ratio of sales cost to be increased
Ratio of sales cost in domestic pharmaceutical companies increased comparing to last year.
Ratio of sales cost, especially, in top pharmaceutical companies increased since they sold a lot of introduced products which...
Huons, Daewon, and Boryeong did dramatic operation and had lots of expenses on distribution and management
Three domestic pharmaceutical companies are being competitive for the development generic lung cancer drug.
On 29th according to MFDS, there are three generic developing companies which have passed bioequivalence Tes...
pharmaceutical industries shows that they maintain good status in their job market and employment
It is shown that pharmaceutical industries are maintaining good job market statues despite the difficult operating environment.
Yuhan, Gukjae and CKD have still shown strongly attached corporate culture and more than...
For the first half of the year, sales of listed pharmaceutical companies are recorded average level while operating profits are recorded lower than averages
For the first half of the year, listed companies are recorded at the average level of revenue growth, but operating profit was poor.
However, net profit is shown in 20%s since non-operating income is increased.
Acco...
Drug Distribution Association develops ‘domestic medicines revival campaign’
Drug distribution industries progress ‘domestic medicines revival campaign’ to develop domestic pharmaceutical industries and reduce health insurance finance.
Korea Drug Distribution Association will move forward to ...
Pharmaceuticals R&D is on the rail now… Hanmi, LG invest 20percents
Domestic pharmaceutical companies’ commitment to R&D is on the rail now.
According to the 2014 first half R&D status analysis by dailypharm, the companies put about 449.6 billion won which is 6.5 percent of its sales...
Three pharmaceutical companies are launched to develop generic drugs of Iressa which costs about 30 billion won
Three domestic pharmaceutical companies are being competitive for the development generic lung cancer drug.
On 29th according to MFDS, there are three generic developing companies which have passed bioequivalence Tes...
Patients are suffering now since Health Insurance Review & Assessment Service and Pfizer are at tug-of-war over the insurance benefit
Non-small cell lung cancer(NSCLC) drug, Xalkori, is now on the issue of being insurance benefit. NSCLC patients are suffering from a tug-of-war between HIRA and Pfizer.
Not only Pfizer, HIRA also recognizes the need ...
